EZH2 and neoplasm: Despite the lack of a sizable number of EZH2 expressing T lymphocytes, we explored the expression of the costimulatory molecule PD‐1 and its ligand PD‐L1 in order to identify potential treatment window of the host immune system being, as expected, tumor cells always negative.